Dynavax Technologies | DVAX - Selling And Administration Expenses



Dynavax Technologies reported $41.54M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Adma Biologics USD 23.37M 1.22M Jun/2025
Amgen USD 1.69B 4M Jun/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
Biogen USD 583.8M 11.3M Jun/2025
BioMarin Pharmaceutical USD 232.28M 26.16M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Dynavax Technologies USD 41.54M 64.79M Jun/2025
Gilead Sciences USD 1.36B 100M Jun/2025
Glaxosmithkline GBP 2.09B 609M Jun/2025
Merck USD 2.63B 104M Jun/2025
Neurocrine Biosciences USD 286.3M 9.8M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Regeneron Pharmaceuticals USD 634.2M 1.2M Jun/2025
Roche Holding CHF 3.61B 381M Dec/2024
Sarepta Therapeutics USD 69.89M 63.74M Jun/2025
TG Therapeutics USD 12.04M 38.29M Jun/2025
Vertex Pharmaceuticals USD 424.6M 28.2M Jun/2025